Elite Pharmaceuticals, Inc. Increase (Decrease) in Accounts Payable
Elite Pharmaceuticals, Inc. (ELTP) reported Increase (Decrease) in Accounts Payable of -$462.08 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$462.08K, a 121.68% decline year-over-year.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$468.67K.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $3.10M, a 19.69% decline year-over-year.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$1.66M.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2026 was $3.10M, a 1172.56% increase from fiscal 2025.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2025 was $243.28K, a 1022.08% increase from fiscal 2024.
- Elite Pharmaceuticals, Inc. increase (decrease) in accounts payable for fiscal 2024 was $21.68K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$462.08K 10-Q · filed 2026-08-13 | -$930.74K derived: sum of 2 quarters · filed 2026-08-13 | $2.17M derived: sum of 3 quarters · filed 2026-08-13 | $502.50K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$468.67K derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $2.63M derived: sum of 2 quarters · filed 2026-06-29 | $964.58K derived: sum of 3 quarters · filed 2026-06-29 | $3.10M 10-K · filed 2026-06-29 |
| 2025-12-31 | $3.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $1.43M derived: sum of 2 quarters · filed 2026-02-17 | $3.56M 10-Q · filed 2026-02-17 | $681.75K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-09-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | $467.04K 10-Q · filed 2025-11-14 | -$2.42M derived: sum of 3 quarters · filed 2026-08-13 | $1.44M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $2.13M 10-Q · filed 2026-08-13 | -$751.49K derived: sum of 2 quarters · filed 2026-08-13 | $3.11M derived: sum of 3 quarters · filed 2026-08-13 | $2.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$2.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-06-29 | $974.30K derived: sum of 2 quarters · filed 2026-06-29 | $350.55K derived: sum of 3 quarters · filed 2026-06-29 | $243.28K 10-K · filed 2026-06-29 |
| 2024-12-31 | $3.86M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-02-17 | $3.23M derived: sum of 2 quarters · filed 2026-02-17 | $3.13M 10-Q · filed 2026-02-17 | $3.12M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-09-30 | -$623.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-11-14 | -$731.03K 10-Q · filed 2025-11-14 | -$734.84K derived: sum of 3 quarters · filed 2025-11-14 | -$1.87M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$107.27K 10-Q · filed 2025-08-14 | -$111.08K derived: sum of 2 quarters · filed 2025-08-14 | -$1.25M derived: sum of 3 quarters · filed 2025-08-14 | $486.29K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-30 | -$1.14M derived: sum of 2 quarters · filed 2025-06-30 | $593.57K derived: sum of 3 quarters · filed 2025-06-30 | $21.68K 10-K · filed 2025-06-30 |
| 2023-12-31 | -$1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $597.38K derived: sum of 2 quarters · filed 2025-02-13 | $25.49K 10-Q · filed 2025-02-13 | |
| 2023-09-30 | $1.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-14 | $1.16M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$571.88K 10-Q · filed 2024-08-14 |